Key result
VASP-guided clopidogrel maintenance doses significantly reduced the rate of MACE compared to fixed doses (9.3% vs 20.4%; P=0.008) in patients with clopidogrel resistance after PCI.
Why the study?
Does VASP-guided adjusted clopidogrel maintenance dosing reduce major adverse cardiovascular events in patients with clopidogrel resistance undergoing PCI?
RCT (n=306)
randomized
No
Does VASP-guided adjusted clopidogrel maintenance dosing reduce major adverse cardiovascular events in patients with clopidogrel resistance undergoing PCI?
Absolute Event Rate: 9.3% vs 20.4%
p-value: p=0.008
Adjusting clopidogrel maintenance doses based on platelet reactivity monitoring significantly reduces MACE without increasing bleeding in clopidogrel-resistant patients undergoing PCI.
No takes yet. Share an insight, caveat, or question.
Supports VASP-guided dosing in resistant post-PCI patients; extends RCT evidence for platelet reactivity monitoring to optimize outcomes.
Wang et al. (2011) conducted an RCT in clopidogrel resistance (n=306). VASP-guided clopidogrel maintenance doses vs. Fixed doses was evaluated on Rate of major adverse cardiovascular events (MACE) (p=0.008). VASP-guided clopidogrel maintenance doses significantly reduced the rate of MACE compared to fixed doses (9.3% vs 20.4%; P=0.008) in patients with clopidogrel resistance after PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: